153505-37-4

Basic information

• Product Name: 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98
• Synonyms: 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98;4-Bromo-5-fluoro-1,2-phenylenediamine 98%;4-Bromo-5-fluorobenzene-1,2-diamine 97%;4-Bromo-5-fluorophenylene-1,2-diamine, 4-Bromo-1,2-diamino-5-fluorobenzene;1,2-BenzenediaMine, 4-broMo-5-fluoro-;4-Bromo-5-fluorophenylene-1,2-diamine, 1-Bromo-4,5-diamino-2-fluorobenzene;4-Bromo-5-fluorobenzene-1,2-diamine97%
• CAS NO: 153505-37-4
• Molecular Formula: C₆H₆BrFN₂
• Molecular Weight: 205.0294
• Mol File: 153505-37-4.mol

Chemical Properties

• Boiling Point: 297 °C at 760 mmHg
• Flash Point: 133.4 °C
• Appearance: /
• Density: 1.792 g/cm³
• Vapor Pressure: 0.00139mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.15±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98(153505-37-4)
• EPA Substance Registry System: 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98(153505-37-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 153505-37-4(Hazardous Substances Data)

Usage

Uses

Used in Hair Dye Industry:
4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98 is used as a colorant for hair dyes due to its capacity to create long-lasting color by binding to hair proteins. Its presence in hair dye formulations contributes to the development of a wide range of shades and tones.
Used in Pigment Industry:
In the pigment industry, 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98 is utilized as a pigment precursor, enabling the production of stable and vibrant pigments for various applications, including cosmetics and other industrial uses.
Safety Considerations:
It is crucial to handle 4-BROMO-5-FLUORO-1,2-PHENYLENEDIAMINE 98 with care due to its potential hazards. Proper storage and handling in accordance with safety guidelines are essential to prevent any adverse effects during its use in manufacturing processes.

InChI:InChI=1/C6H6BrFN2/c7-3-1-5(9)6(10)2-4(3)8/h1-2H,9-10H2

Upstream product

• 153505-36-3 4-bromo-5-fluoro-2-nitroaniline 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 929279-27-6 N-(4-bromo-5-fluoro-2-nitrophenyl)-2,2,2-trifluoroacetamide 
• 656-65-5 3-fluoro-4-bromophenylamine 

Downstream Products

• 1449475-37-9 4-fluoro-5-neopentylbenzene-1,2-diamine 
• 1276025-35-4 (S)-3-(4,5-diamino-2-fluorophenyl)-4-phenyloxazolidin-2-one 
• 1008360-84-6 5-bromo-6-fluoro-1H-benzo[d]imidazole 

Relevant articles and documents

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.